The Patent Finder
3P

3B Pharmaceuticals GmbH

First filing 2009
OverviewNotableFeesChangesFamiliesPatent listSources & methods

5 patents currently held

13 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Dec 2033. from the record

Of the 13 now held by other companies, 9 were conveyed to Takeda Pharmaceutical Company Limited in the filing they arrived in, and 4 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2033
Next term end
4
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Formerly held, still cited

Notable
Cited by 10 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
conveyed to Baxter International Inc., Baxter Healthcare S.A. - now held by Takeda Pharmaceutical Company Limited
Ends Feb 2031 · Low confidence
Also notable
The most cited patent in this portfolio, cited by 27 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2031.
Ends Apr 2031 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Oct 28, 2027
    The maintenance fee for Determination of Binding Constants by Means of Equilibrium Shifting (US 10,634,663) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 19, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 5 of 5

PatentTitleStatusExpiresConfidence
US 10,961,199Neurotensin Receptor Ligands
In force
 · High confidence
In forceHigh confidence
US 10,634,663Determination of Binding Constants by Means of Equilibrium Shifting
In force
 · High confidence
In forceHigh confidence
US 10,799,605Conjugate Comprising a Neurotensin Receptor Ligand and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,734,259Compounds Comprising a Fibroblast Activation Protein Ligand and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 12,427,210Compounds Comprising a Fibroblast Activation Protein Ligand and Use Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 5: 13 patents in force now held by others · 2 patents ended · 16 applications pending · 7 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited